The Day In Review: Rampant Deal Activity In Biotech

10/17/2006 4:59:28 PM

October 17, 2006 -- Lilly bid $2.1 billion for ICOS, its partner on the erectile dysfunction drug Cialis; InterMune partnered its protease inhibitor program, including a hepatitis C drug, with Roche; Genzyme trumped the Millennium bid for AnorMED; Merck won FDA approval for Januvia, its oral diabetes drug; Memory Pharma said its Alzheimer's drug is on clinical hold pending FDA review of toxicology reports; the FDA accepted the new drug application for an extended release version of Zyflo , an asthma drug from Critical Therapeutics; and Inovio acquired DNA delivery and expression technology from Valentis. The Centient Biotech 200™ closed with a fractional gain at 3947, an increase of .01%. More details...

Read at ChinaBio Today [Sub. Required]

Read Article at

Related Companies

News Categories

• ChinaBio Today [Sub. Required]

• Memory Pharmaceuticals Corp.

• Roche

• Merck & Co., Inc.

• AnorMED (Acquired by Genzyme)

• Eli Lilly and Company

• Millennium: The Takeda Oncology Company

• Genzyme Corporation